Untitled Document
OHSU Where Healing, Teaching and Discovery Come Together
OHSU Search OHSU OHSU Site Map Contact
OHSU Division of Hematology and Medical Oncology
About the Division Care Centers Patient Resources Our Faculty Research and Education News and Events
Dedicated to the study and treatment of cancer and disorders of the blood.

 
undefined

Our Faculty

Joshi J. Alumkal, M.D.
 Assistant Professor of Medicine

Specialty: Prostate Cancer and other
Genitourinary Malignancies
 

Administrative Office: 503-494-8534
Clinic: 503-494-6594

 

Dr. Alumkal's research interest is cancer epigenetics, the study of heritable and potentially reversible gene silencing events in cancer.  His work focuses on the identification of better diagnostic and prognostic biomarkers and therapeutic agents, which might lead to gene re-expression, in prostate cancer.  Clinically, he is interested in patients with all stages of prostate cancer and other genitourinary malignancies.

 
Appointments
  • Assistant Professor of Medicine, Department of Medicine, Hematology & Medical Oncology

 
Professional Education and Training
  • 1994 Bachelor of Arts in Biology, Summa Cum Laude, University of Texas at Austin
  • 1998 Doctorate in Medicine, Baylor College of Medicine, Houston, TX
  • 1998-2001 Resident in Internal Medicine, UT-Southwestern Medical Center, Dallas, TX
  • 2001-2002 Chief Resident in Internal Medicine, UT-Southwestern Medical Center, Dallas, TX
  • 2002-2006 Clinical Fellow in Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
  • 2006 - current Assistant Professor of Medicine, OHSU, Department of Medicine, Hematology & Medical Oncology
Personal
Other
  • Board Certified in Internal Medicine
  • Board Certified in Medical Oncology
 
Selected Publications
  • Through the looking glass.
    • Alumkal JJ.
    Blood. 2009 Oct 15;114(16):3363-4. No abstract available. PMID: 19833849 [PubMed - in process]

     

  • Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6.
    • Gibbs A, Schwartzman J, Deng V, Alumkal J.
    Proc Natl Acad Sci U S A    . 2009 Sep 29;106(39):16663-8. Epub 2009 Sep 15. PMID: 19805354 [PubMed - in process]

     

  • Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes.
    • Dillard T, Yedinak CG, Alumkal J, Fleseriu M.
    Pituitary    . 2009 Jul 29. [Epub ahead of print] PMID: 19639414 [PubMed - as supplied by publisher]

     

  • Effect of DNA methylation on identification of aggressive prostate cancer.
    • Alumkal JJ, Zhang Z, Humphreys EB, Bennett C, Mangold LA, Carducci MA, Partin AW, Garrett-Mayer E, DeMarzo AM, Herman JG.
    Urology    . 2008 Dec;72(6):1234-9. Epub 2008 Apr 2. PMID: 18387661 [PubMed - indexed for MEDLINE]

     

  • hADA2a and hADA3: new players in beta-catenin signaling.
    • Van Hook K, Alumkal J, Lopez CD.
    Cancer Biol Ther. 2008 Jan;7(1):129-30. Epub 2008 Feb 11. No abstract available. PMID: 18347424 [PubMed - indexed for MEDLINE]

     

  • Early use of chemotherapy in conjunction with radical prostatectomy.
    • Alumkal JJ, Carducci MA.
    Clin Prostate Cancer. 2004 Dec;3(3):144-9. Review. PMID: 15636680 [PubMed - indexed for MEDLINE]

     

  • Surgery-associated factor VIII inhibitors in patients without hemophilia.
    • Alumkal J, Rice L, Vempathy H, McCarthy JJ, Riggs SA.
    Am J Med Sci. 1999 Nov;318(5):350-2. PMID: 10555100 [PubMed - indexed for MEDLINE]

Search PubMed for more publications